【摘要】目的探讨连续性肾脏替代治疗(continuous renal replacement therapy,CRRT)非计划下机的相关因素，为临床CRRT 质量管理提供参考依据。方法采用方便抽样的方法进行前瞻性研究，2019 年3 月～2019 年6 月行CRRT 治疗的159 例重症患者，统计CRRT 非计划下机的例次，并分析相关危险因素。结果346 例次CRRT 治疗中非计划下机50 例次(14.45%)，平均治疗时间(19.00± 15.58) h。多因素回归分析提示静脉压、跨膜压(transmembrane pressure，TMP)、凝血酶原时间(prothrombin time，PT)、活化部分凝血活酶时间(activated partial thromboplastin time，APTT)、红细胞压积、抗凝方式、护士负责机器数量是CRRT 治疗中非计划下机的危险因素(OR 值分别为1.022，1.045，0.537，0.502，4.422，12.611，1.021；95% CI 值分别为1.002～1.043，1.023～1.078，0.326～0.885，0.298～0.818，4.035～4.972，9.900～16.223，0.810～1.265；P 值分别为0.043，0.014，0.016，0.019，0.027，0.043，0.001)。结论在实施CRRT 治疗过程中，应注意观察压力监测值的变化及凝血指标、红细胞压积指标，选择合适的抗凝剂和剂量，管理者根据情况合理安排护士工作量，从而降低非计划下机的发生率。
【Abstract】Objective T o explore the related factors of unexpected interruption of continuous renal replacement therapy (CRRT), and to provide the information about clinical CRRT quality management. Methods This was a prospective study using the convenient sampling method.Atotal of 159 patients undergoingCRRTdue to severe illnesses from March 2019 to June 2019 were enrolled in this study. The number of unexpected interruptions of CRRT was recorded and the related factors were analyzed. Results In the 346 CRRT treatments, 50 patientstimes of unplanned cessation of CRRT (14.45%) occurred, and the average treatment time was 19.00 ± 15.58 hours. Multivariate regression analysis revealed that venous pressure (OR=1.022, 95% CI=1.002～1.043, P=0.043), transmembrane pressure (TMP; OR=1.045, 95% CI=1.023～1.078, P=0.014), prothrombin time
(PT; OR=0.537, 95% CI=0.326～0.885, P=0.016), activated partial thromboplastin time (APTT; OR=0.502, 95% CI=0.298～0.818, P=0.019), hematocrit (OR=4.422, 95% CI=4.035~4.972, P=0.027), anticoagulation method (OR=12.611, 95% CI= 9.900 ~16.223, P=0.043), and number of nurses responsible for the machine (OR=1.021, 95% CI=0.810~1.265, P=0.001) were the risk factors for unplanned cessation of CRRT. Conclusion During the implementation of CRRT, changes of pressure value, coagulation indicators and hematocrit indicators must be carefully monitored, anticoagulants and their doses must be appropriately adjusted, and the workload of the nurses must be properly arranged to reduce the rate of unexpected interruption of CRRT.
[1] Rewa O, Villeneuve PM, Lachance P, et al. Quality indicators of continuous renal replacement therapy (CRRT) care in critically ill patients: a systematic review[J]. Intensive Care Med,2017:750-763.
[2]张凌. 连续性肾脏替代治疗体外循环寿命的影响因素[J]. 临床肾脏病杂志,2015, 15(10):580-584.
[3]费素定, 金静芬, 王海燕. 连续性肾脏替代治疗非计划性下机时间相关因素的研究[J]. 中华护理杂志,2015, 50(1):57-61.
[4]Gattas D, Rajbhandari D, Bradford C, et al. A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically III Adults[J]. Crit Care Med, 2015, 43(8):1622-1629.
[5]陈香美. 血液净化标准操作规程[M]. 北京：人民军医出版社,2010:43-49.
[6]查丽玲,周松,王婧, 等. ICU患者持续性肾脏替代治疗非计划性下机相关因素的研究[J]. 护理学杂志,2017, 32(13):31-34.
[7]Kakajiwala A, Jemielita T, Hughes JZ, et al. Membrane pressures predict clotting of pediatric continuous renal replacement therapy circuits[J]. Pediatr Nephrol 2017, 32(7):1251-1261.
[8]Baldwin I, Fealy N. Nursing for renal replacement therapies in the intensive care unit：historical，educational，and protocol review[J]. Blood Purif, 2009, 27(2):174-181.
[9]Wetering J van de, Westendorp RG , van der Hoeven JG , et al. Heparin use in continuous renal replacement procedures: The struggle between filter coagulation and patient hemorrhage[J]. J Am Soc Nephrol. 1996, 7(1):145-150.
[10]宋利, 符霞, 全梓林，等. 持续性肾脏替代治疗体外循环堵塞相关因素分析[J]. 护理研究, 2015, 29(5):1608-1612.
[11]FU X, Liang X, Song L, et al. Building and validation of a prognostic model for predicting extracorporeal circuit clotting in patients with continuous renal replacement therapy[J]. Int Urol Nephrol, 2014(46):801-807.
[12]洪欢, 彭松, 张琳.四种抗凝方法对连续静脉-静脉血液滤过术中滤器寿命的影响及安全性[J]. 山东医药,2016, 56(29):88-90.
[13]S?k G, Demirbuga A, Annayev A, et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill children[J]. Int J Artif Organs, 2019, 00(0):1-7.
[14] Dirkes S, Wonnacott R. Continuous Renal Replacement Therapy and Anticoagulation: What Are the Options[J]? Crit Care Nurse 2016, 36(2):34-41.
[15] Meersch M, Küllmar M, Wempe C, et al.SepNet Critical Care Trials Group. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial[J]. BMJ Open 2019, 9(1):e024411.
[16]王兰, 于重燕, 田君叶．CRRT人力资源配置与使用现状调查[J]. 护理学杂志,2014, 29(19):56-57
[17] 方秀花, 梅本刚: 连续性肾脏替代治疗非计划性下机原因分析及护理对策[J]. 重庆医学, 2016, 45(27):3881-3883.
[18] Baldwin I, Jones D, Carty P, et al. Continuous Renal Replacement Therapy Without Anticoagulation: Top Ten Tips to Prevent Clotting[J]. Blood Purif ,2019:1-
